Study of MMLV RT- binding with DNA using surface plasmon resonance biosensor

Acta Biochimica et Biophysica Sinica

Volumn 37, Issue 9, 2005, Pages 634-642

  Wu, Lei ^a   Huang, Ming Hui ^b   Zhao, Jian Long ^a   Yang, Meng Su ^b  

^a SHANGHAI INSTITUTE OF MICROSYSTEM AND INFORMATION TECHNOLOGY   (China)

^b CITY UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Inhibitor; Kinetics; Reverse transcriptase; Surface plasmon resonance biosensor

Indexed keywords

MOLONEY MURINE LEUKEMIA VIRUS;

DNA; EFAVIRENZ; NEVIRAPINE; OXAZINE DERIVATIVE; PRIMER DNA; QUERCETIN; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SINGLE STRANDED DNA;

ARTICLE; DNA DAMAGE; DNA TEMPLATE; DRUG EFFECT; ENZYMOLOGY; GENETICS; KINETICS; METABOLISM; MOLONEY LEUKEMIA ONCOVIRUS; PHYSIOLOGY; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE; SENSITIVITY AND SPECIFICITY; SURFACE PLASMON RESONANCE;

DNA; DNA DAMAGE; DNA PRIMERS; DNA, SINGLE-STRANDED; KINETICS; MOLONEY MURINE LEUKEMIA VIRUS; NEVIRAPINE; OXAZINES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; QUERCETIN; REVERSE TRANSCRIPTASE INHIBITORS; RIBONUCLEASE H, CALF THYMUS; RNA-DIRECTED DNA POLYMERASE; SENSITIVITY AND SPECIFICITY; SURFACE PLASMON RESONANCE; TEMPLATES, GENETIC;

EID: 26944486682     PISSN: 16729145     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1745-7270.2005.00088.x     Document Type: Article

References (30)

1. Arnold Eicalournal, Georgiadis MM, Jessen SM, Ogata CM, Telesnitsky A, Goff SP, Hendrickson WA. Mechanistic implications from the structure of a catalytic fragment of moloney murine leukemia virus reverse transcriptase. Structure 1995, 3: 879-892
2. Motakis D, Parniak MA. A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002, 46: 1851-1856
3. Rittinger K, Divita G, Goody RS. Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. Proc Natl Acad Sci USA 1995, 92: 8046-8049
4. Huang H, Chopra R, Verdine GL, Harrison SC. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance. Science 1998, 282: 1669-1675
5. Maga G, Ubiali D, Salvetti R, Pregnolato M, Spadari S. Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes. Antimicrob Agents Chemother 2000, 44: 1186-1194
6. Yang SS, Cragg GM, Newman DJ, Bader JP. Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program. J Nat Prod 2001, 64: 265-277
7. Ono K, Nakane H, Fukushima M, Chermann JC, Barre-Sinoussi F. Differential inhibitory effects of various flavonoids on the activities of reverse transcriptase and cellular DNA and RNA polymerases. Eur J Biochem 1991, 190: 469-476
8. Tewtrakul S, Nakamura N, Hattori M, Fujiwara T, Supavita T. Flavanone and flavonol glycosides from the leaves of Thevetia peruviana and their HIV-1 reverse transcriptase and HIV-1 integrase inhibitory activities. Chem Pharm Bull 2002, 50: 630-635
9. Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease and cancer. Pharmacol Rev 2000, 52: 673-751
10. Tsoi PY, Yang M. Surface plasmon resonance study of the molecular recognition between polymerase and DNA containing various mismatches and conformational changes of DNA-protein complexes. Biosens Bioelectron 2004, 19: 1209-1218
11. Tsoi PY, Yang J, Sun YT, Sui SF, Yang MS. Surface plasmon resonance study of DNA polymerases binding to template/primer DNA duplexes immobilized on supported lipid monolayers. Langmuir 2000, 16: 6590-6596
12. Gorshkova II, Rausch JW, le Grice SF, Crouch RJ. HIV-1 reverse transcriptase interaction with model RNA-DNA duplexes. Anal Biochem 2001, 291: 198-206
13. Linnell J, Mott R, Field S, Kwiatkowski DP, Ragoussis J, Udalova IA. Quantitative high-throughput analysis of transcription factor binding specificities. Nucleic Acids Res 2004, 32: e44
14. Wohrl BM, Georgiadis MM, Telesnitsky A, Hendrickson WA, le Grice SF. Footprint analysis of replicating murine leukemia virus reverse transcriptase. Science 1995, 267: 96-99
15. Sjolander S, Urbaniczky C. Integrated fluid handling system for biomolecular interaction analysis. Anal Chem 1991, 63: 2338-2345
16. Luo J, Zhou J, Zou W, Shen P. Antibody-antigen interactions measured by surface plasmon resonance: Global fitting of numerical integration algorithms. J Biochem 2001, 130: 553-559
17. Wohrl BM, Krebs R, Goody RS, Restle T. Refined model for primer/template binding by HIV-1 reverse transcriptase: Pre-steady-state kinetic analyses of primer/template binding and nucleotide incorporation events distinguish between different binding modes depending on the nature of the nucleic acid substrate. J Mol Biol 1999, 292: 333-344
18. Farmerie WG, Loeb DD, Casavant NC, Hutchison CA 3rd, Edgell MH, Swanstrom R. Expression and processing of the AIDS virus reverse transcriptase in E. coli. Science 1987, 236: 305-308
19. Telesnitsky A, Goff SP. RNase H domain mutations affect the interaction between Moloney murine leukemia virus reverse transcriptase and its primer-template. Proc Natl Acad Sci USA 1993, 90: 1276-1280
20. Tsoi PY, Yang MS. Kinetic study of various binding modes between human DNA polymerase β and different DNA substrates by surface-plasmon-resonance biosensor. Biochem J 2002, 361: 317-325
21. Lipschultz CA, Li Y, Smith-Gill S. Experimental design for analysis of complex kinetics using surface plasmon resonance. Methods 2000, 20: 310-318
22. Spence RA, Kati WM, Anderson KS, Johnson KA. Mechanism of inhibition of HIV-I reverse transcriptase by nonnucleoside inhibitors. Science 1995, 267: 988-993
23. Sluis-Cremer N, Tachedjian G. Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules. Eur J Biochem 2002, 269: 5103-5111
24. Tachedjian G, Goff SP. The effect of NNRTIs on HIV reverse transcriptase dimerization. Curr Opin Investig Drugs 2003, 4: 966-973
25. Tachedjian G, Aronson HE, de los Santos M, Seehra J, McCoy JM, Goff SP. Role of residues in the tryptophan repeat motif for HIV-1 reverse transcriptase dimerization. J Mol Biol 2003, 326: 381-396
26. Tachedjian G, Orlova M, Sarafianos SG, Arnold E, Goff SP. From the Cover: Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. Proc Natl Acad Sci USA 2001, 98: 7188-7193
27. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256: 1783-1790
28. Pauwels R, Peletskaya EN, Kogon AA, Tuske S, Arnold E, Hughes SH. Nonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNA. J Virol 2004, 78: 3387-3397
29. Mizushina Y, Iida A, Ohta K, Sugawara F, Sakaguchi K. Novel triterpenoids inhibit both DNA polymerase and DNA topoisomerase. Biochem J 2000, 350: 757-763
30. Kim HJ Woo ER, Shin CG, Park H. A new flavonol glycoside gallate ester from Acer okamotoanum and its inhibitory activity against human immunodeficiency virus-1 (HIV-1) integrase. J Nat Prod 1998, 61: 145-148